CDK2-IN-13

• Description:

  CDK2-IN-13 (Compound 15) is a CDK2 inhibitor with an IC50 of 12 µM. CDK2-IN-13 can be used in research of cancer[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302-H315-H319-H335

• Target:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cdk2-in-13.html

• Purity:

  98.20

• Solubility:

  DMSO : 11.11 mg/mL (ultrasonic; warming; adjust pH to 11 with NaOH; heat to 60°C)

• Smiles:

  CN1C=NC2=C(N=C(N=C21)Cl)NCC3=CC=CC=C3

• Molecular Formula:

  C13H12ClN5

• Molecular Weight:

  273.73

• Precautions:

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501

• References & Citations:

  [1]Havlícek L, et al. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem. 1997 Feb 14;40 (4) :408-12.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture and light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  101622-53-1